# US 2021/0277071 A1 · Hybrid neurotoxins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277071 A1
- Document ID: US20210277071A1
- Status: Published application
- Kind: A1
- Application number: 16/325,046
- Filed: 2017-09-28
- Published: 2021-09-09
- Earliest claimed: 2016-09-29
- Assignees: Ipsen Biopharm Ltd.
- Applicants: Ipsen Biopharm Limited
- Inventors: Elena FONFRIA-SUBIROS; David BURGIN
- Web page: https://patentgrep.com/patent/US20210277071A1

## CPC

- C07K 14/33: from Clostridium (G)
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 35/00: Antineoplastic agents
- C07K 14/245: Escherichia (G)
- C07K 14/28: from Vibrionaceae (F)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to hybrid neurotoxins comprising a clostridial light chain and a selective ganglioside binding moiety and to their use in therapy.

## Claims

### Claim 1

A hybrid neurotoxin comprising a clostridial light chain (L) and a selective ganglioside binding moiety, wherein said selective ganglioside binding moiety is not a clostridial HCC or a HC domain.

### Claim 2 (depends on 1)

A hybrid neurotoxin according to claim 1, wherein said hybrid neurotoxin further comprises a translocation moeity.

### Claim 3 (depends on 2)

A hybrid neurotoxin according to claim 2, wherein said translocation moiety is selected from the group consisting of a clostridial HN domain, a Cholera toxin A2 subunit (CtxA2), and cell penetrating peptides.

### Claim 4 (depends on 2, 3)

A hybrid neurotoxin according to claim 2 or 3, wherein said translocation moiety is a clostridial HN domain, and wherein said hybrid neurotoxin comprises an activation site between the light chain and the clostridial HN domain.

### Claim 5 (depends on 1, 2, 3, 4)

A hybrid neurotoxin according to any one of claims 1 to 4, wherein said hybrid neurotoxin further comprises a clostridial HCN and/or a HCC domain.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A hybrid neurotoxin according to any one of claims 1 to 5, wherein said selective ganglioside binding moiety binds to one or more gangliosides selected from the group consisting of GM1 such as GM1a or GM1b, GM2, GM3 such as NeuAc GM3 or NeuGc GM3, GM4, GD1a, GalNAc-GD1a, GT1a, GT1b, GQ1b, GD2, GD3, and any combination thereof.

### Claim 7 (depends on 6)

A hybrid neurotoxin according to claim 6, wherein said selective ganglioside binding moiety binds to GM1, and wherein said selective ganglioside binding moiety comprises one or more Cholera toxin B subunits (CtxB) or E. coli heat labile enterotoxin (LT).

### Claim 8 (depends on 7)

A hybrid neurotoxin according to claim 7, wherein said selective ganglioside binding moiety comprises one or more Cholera toxin B subunits (CtxB) and said light chain is covalently bound to said one or more Cholera toxin B subunits (CtxB).

### Claim 9 (depends on 7)

A hybrid neurotoxin according to claim 7, wherein said selective ganglioside binding moiety comprises one or more Cholera toxin B subunits (CtxB) and said hybrid neurotoxin comprises a Cholera toxin A2 subunit (CtxA2), wherein said CtxA2 is covalently bound to said clostridial light chain, and wherein said CtxB forms a non covalent link with said clostridial light chain.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A hybrid neurotoxin according to any one of claims 1 to 9, wherein said clostridial light chain is from a BoNT type A, type B, type Cl, type D, type E, type F or type G or a TeNT.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleotide sequence encoding a hybrid neurotoxin according to any one of claims 1 to 10.

### Claim 12 (depends on 11)

A vector comprising a nucleotide sequence according to claim 11.

### Claim 13 (depends on 11, 12)

A cell comprising a nucleotide sequence according to claim 11 or a vector according to claim 12.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising a hybrid neurotoxin according to any one of claims 1 to 10.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

A hybrid neurotoxin according to any one of claims 1 to 10 or a pharmaceutical composition according to claim 14 for use in therapy.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

A hybrid neurotoxin according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 14, for use in treating a limb disorder associated with unwanted neuronal activity, wherein said selective ganglioside binding moiety binds to one or more gangliosides selected from GM1a, GM1b, GD1a and GalNAc-GD1a.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

A hybrid neurotoxin according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 14, for use in treating a head or neck disorder associated with unwanted neuronal activity, wherein said selective ganglioside binding moiety binds to one or more gangliosides selected from GT1a and GQ1b.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

A hybrid neurotoxin according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 14, for use in treating sialorrhea, wherein said selective ganglioside binding moiety binds to the ganglioside moiety GM1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

A hybrid neurotoxin according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 14, for use in treating cancer, wherein said selective ganglioside binding moiety binds to one or more gangliosides selected from NeuAc GM3, NeuGc GM3, GM2, GM1, GD3 and GD2.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

Non-therapeutic use of a hybrid neurotoxin according to any one of claims 1 to 10 or of a pharmaceutical composition according to claim 14, for treating an aesthetic condition.
